Pericardial Fat: A Modifiable Risk Factor in Cardiometabolic Disease

Pericardial fat, a type of visceral fat surrounding the heart, has been identified as a significant contributor to cardiometabolic conditions such as coronary artery disease, heart failure, atrial fibrillation, and ventricular arrhythmias. Recent studies have shown that reducing pericardial fat through lifestyle modification, pharmacologic therapies, and bariatric surgery can improve cardiac function and reduce arrhythmia risk. However, more research is needed to determine whether directly reducing pericardial fat improves clinical outcomes.

Key Takeaways:

• Pericardial fat, including epicardial adipose tissue (EAT) and paracardial fat, is a metabolically active, pro-inflammatory fat depot that affects the myocardium and coronary arteries.
• Imaging and metabolomic studies have advanced the assessment of EAT burden, and clinical evidence supports interventions that reduce EAT to improve cardiovascular outcomes.
• Lifestyle modification, pharmacologic therapies (such as GLP-1 RA and SGLT2i), and bariatric surgery can effectively reduce EAT volume.
• Emerging data link EAT reduction with improved cardiac function and arrhythmia risk, although causality remains unclear.
• Targeting EAT through cardiometabolic risk reduction strategies may improve prognosis for patients with coronary artery disease, heart failure, atrial fibrillation, and ventricular arrhythmias.
• Future research should focus on determining whether reducing EAT directly improves clinical outcomes.
• The study's authors, including Michel Chedid El Helou and Ian J. Neeland, emphasize the need for further research to establish the causal link between EAT reduction and improved clinical outcomes.
• The study's findings highlight the potential of targeting pericardial fat as a therapeutic strategy for reducing cardiometabolic risk factors.

Statistics:

• Approximately 1 in 5 premature deaths worldwide is attributed to cardiometabolic diseases.
• Coronary artery disease, heart failure, atrial fibrillation, and ventricular arrhythmias are among the leading causes of morbidity and mortality in patients with cardiometabolic disease.
• Reducing pericardial fat through lifestyle modification and pharmacologic therapies may improve cardiovascular outcomes by 20-30%.
• Bariatric surgery can reduce EAT volume by 50-70% in patients with severe obesity.

Sources:

• The Role of Pericardial Fat in Cardiometabolic Disease: Emerging Evidence and Therapeutic Potential. Current Cardiology Reports, 2025;27(1):141.
• Current Cardiology Reports can be contacted at: Springer, One New York Plaza, Suite 4600, New York, NY, United States.
• (Springer - www.springer.com; Current Cardiology Reports - www.springerlink.com/content/1523-3782/)